Benutzer: Gast  Login
Titel:

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.

Dokumenttyp:
Journal Article; Article
Autor(en):
von Bubnoff, N; Barwisch, S; Speicher, MR; Peschel, C; Duyster, J
Abstract:
The discovery of tyrosine kinases that, once deregulated, can cause malignancy, allowed the development of specifically acting anti-cancer compounds. In chronic myeloid leukaemia (CML), the Bcr-Abl kinase inhibitor imatinib (STI571, Gleevec) induces impressive response rates. However, resistance occurs especially in advanced phase CML and Ph+ ALL, primarily as a consequence of point mutations within the Bcr-Abl kinase domain that prevent imatinib from binding. To overcome imatinib resistance, al...     »
Zeitschriftentitel:
Cell Cycle
Jahr:
2005
Band / Volume:
4
Heft / Issue:
3
Seitenangaben Beitrag:
400-6
Sprache:
eng
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/15738656
Print-ISSN:
1538-4101
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Humangenetik
 BibTeX